WO2023101061A1 - Patch for allergy prevention - Google Patents
Patch for allergy prevention Download PDFInfo
- Publication number
- WO2023101061A1 WO2023101061A1 PCT/KR2021/018172 KR2021018172W WO2023101061A1 WO 2023101061 A1 WO2023101061 A1 WO 2023101061A1 KR 2021018172 W KR2021018172 W KR 2021018172W WO 2023101061 A1 WO2023101061 A1 WO 2023101061A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- patch
- coating layer
- allergy
- preventing
- preventing allergy
- Prior art date
Links
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 38
- 230000007815 allergy Effects 0.000 title claims abstract description 33
- 208000026935 allergic disease Diseases 0.000 title claims abstract description 26
- 230000002265 prevention Effects 0.000 title claims abstract 3
- 239000000739 antihistaminic agent Substances 0.000 claims abstract description 26
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims abstract description 20
- 230000001387 anti-histamine Effects 0.000 claims abstract description 20
- 230000000694 effects Effects 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 229940125715 antihistaminic agent Drugs 0.000 claims abstract description 6
- 239000011247 coating layer Substances 0.000 claims description 30
- 239000000758 substrate Substances 0.000 claims description 19
- 239000002872 contrast media Substances 0.000 claims description 12
- 239000000017 hydrogel Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 6
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- -1 piperinhydrinate Chemical compound 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000004381 surface treatment Methods 0.000 claims description 3
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 claims description 2
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 claims description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 2
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims description 2
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 claims description 2
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 claims description 2
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 claims description 2
- 229960004574 azelastine Drugs 0.000 claims description 2
- 229960002071 bepotastine Drugs 0.000 claims description 2
- YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 claims description 2
- 229960001803 cetirizine Drugs 0.000 claims description 2
- 229960003291 chlorphenamine Drugs 0.000 claims description 2
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001271 desloratadine Drugs 0.000 claims description 2
- 229960004993 dimenhydrinate Drugs 0.000 claims description 2
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 claims description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 2
- 229960000520 diphenhydramine Drugs 0.000 claims description 2
- 229960001971 ebastine Drugs 0.000 claims description 2
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 claims description 2
- 229960000325 emedastine Drugs 0.000 claims description 2
- KBUZBQVCBVDWKX-UHFFFAOYSA-N emedastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 KBUZBQVCBVDWKX-UHFFFAOYSA-N 0.000 claims description 2
- 229960003449 epinastine Drugs 0.000 claims description 2
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 claims description 2
- 229960003592 fexofenadine Drugs 0.000 claims description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 2
- 230000037406 food intake Effects 0.000 claims description 2
- 235000012631 food intake Nutrition 0.000 claims description 2
- 229960000930 hydroxyzine Drugs 0.000 claims description 2
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims description 2
- 229960004958 ketotifen Drugs 0.000 claims description 2
- 229960001120 levocabastine Drugs 0.000 claims description 2
- ZCGOMHNNNFPNMX-KYTRFIICSA-N levocabastine Chemical compound C1([C@@]2(C(O)=O)CCN(C[C@H]2C)[C@@H]2CC[C@@](CC2)(C#N)C=2C=CC(F)=CC=2)=CC=CC=C1 ZCGOMHNNNFPNMX-KYTRFIICSA-N 0.000 claims description 2
- 229960001508 levocetirizine Drugs 0.000 claims description 2
- 229960003088 loratadine Drugs 0.000 claims description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 2
- 229960001474 meclozine Drugs 0.000 claims description 2
- 229960005042 mequitazine Drugs 0.000 claims description 2
- 229960004114 olopatadine Drugs 0.000 claims description 2
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 claims description 2
- 239000004575 stone Substances 0.000 claims description 2
- 229960001128 triprolidine Drugs 0.000 claims description 2
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 claims description 2
- 150000003431 steroids Chemical class 0.000 abstract description 7
- 201000005569 Gout Diseases 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 4
- 229940039231 contrast media Drugs 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002591 computed tomography Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 229920005594 polymer fiber Polymers 0.000 description 3
- 229920006254 polymer film Polymers 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 241001444063 Aronia Species 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 235000011203 Origanum Nutrition 0.000 description 1
- 240000000783 Origanum majorana Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010038669 Respiratory arrest Diseases 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000011318 facial edema Diseases 0.000 description 1
- 229920005570 flexible polymer Polymers 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940106587 pine bark extract Drugs 0.000 description 1
- 235000020741 pine bark extract Nutrition 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Definitions
- the present invention relates to a patch for preventing side effects caused by an allergic reaction, and relates to a patch for preventing allergy, which includes a coating layer formed on a substrate with a composition containing an antihistamine.
- imaging tests such as computed tomography (CT) and magnetic resonance imaging (MRI) are radiological tests that are used as essential elements for diagnosing diseases.
- CT computed tomography
- MRI magnetic resonance imaging
- the use of a contrast agent in such a CT scan or MRI scan increases the contrast of the image so that lesions can be clearly distinguished, and the number of uses is increasing day by day.
- the contrast medium is injected into the human body, there may be a burning sensation in the face, chest, or abdomen, a smell of medicine in the patient's mouth, and a slight sense of warmth. These are normal reactions felt as the contrast medium spreads through blood vessels in the body.
- contrast agent-related hypersensitivity reactions or adverse reactions that require treatment by medical staff are rare.
- Acute adverse reactions to contrast media range from mild symptoms such as vomiting, hives, and pruritus to severe reactions ranging from trachea constriction, facial edema, hypotensive shock, respiratory arrest, and cardiac arrest.
- the present invention has been made in view of and solving the above-mentioned conventional problems, and an object of the present invention is to provide a patch for preventing allergy that includes a coating layer formed of a composition containing an antihistamine on a substrate.
- the present invention is a substrate; And a coating layer containing an antihistamine formed on at least one surface of the substrate,
- the coating layer provides a patch for preventing allergy that is formed by coating a composition containing an antihistamine.
- a patch containing a composition containing an antihistamine is non-invasive by attaching to the skin, can be used as a preventive measure prior to the onset of side effects caused by allergies, and can be used temporarily until arriving at a hospital. there is.
- steroids are generally used together with antihistamines to treat side effects caused by allergies, but the patch of the present invention does not contain steroids, so it can be used even in cases of gout.
- 1 and 2 are schematic images of a patch according to an embodiment of the present invention.
- the present invention relates to a patch for preventing side effects caused by allergy.
- the patch for preventing allergy of the present invention is a patch containing a composition containing an antihistamine, is non-invasive by being attached to the skin, and exhibits symptoms of side effects due to allergy. It can be used as a preventive measure beforehand, and has the advantage of being used temporarily until arriving at the hospital.
- steroids are generally used together with antihistamines to treat side effects caused by allergies, but the patch of the present invention does not contain steroids, so it can be used even in cases of gout.
- the present invention a substrate; and a coating layer comprising an antihistamine formed on at least one surface of a substrate.
- the patch for preventing allergy of the present invention has a structure in which a substrate 10, a coating layer 20 containing an antihistamine, and a release film 30 are sequentially laminated.
- the substrate may include a polymer film; And it may include any one or more of sheets made of natural fibers or polymer fibers.
- the polymer film includes at least one of polyethylene, polypropylene, polyvinyl chloride, and polyurethane.
- the polymer film may be polyurethane, and when it includes polyurethane, it has an advantage of excellent elasticity.
- the natural fibers include any one or more of cellulose, chitin, chitosan, starch, collagen, and gelatin. When using natural fibers as described above, there is an environmentally friendly advantage.
- the polymer fiber includes at least one of polyvinyl alcohol, polyglycolic acid, polylactic acid, and polycaprolactone.
- the substrate may be polarized by surface treatment using plasma. As described above, polarity is imparted to the surface of the substrate subjected to plasma surface treatment, so that bonding strength with the coating layer can be further improved.
- the substrate is a sheet made of at least one of natural fibers and polymer fibers
- cavities are provided in the sheet, and the cavities are formed vertically based on the cross section of the nonwoven fabric, but either top or bottom may have a closed structure.
- the coating layer is formed including the substrate having the above structure, air can pass between the substrates without flowing down to the lower end of the substrate (sheet).
- the coating layer may be formed by coating a composition containing an antihistamine.
- the coating layer is a site in direct contact with the skin.
- the antihistamines include chlorpheniramine, triprolidine, piperinhydrinate, hydroxyzine, mequitazine, diphenhydramine, and dimenhydrin. dimenhydrinate, meclizine, cetirizine, loratadine, levocetirizine, ebastine, ketotifen, fexofenadine, azela Any one or more of azelastine, desloratadine, bepotastine, olopatadine, emedastine, epinastine, and levocabastine include
- the antihistamine When a patch for preventing allergy is attached to the skin by including the antihistamine in the coating layer, the antihistamine is absorbed into the skin and moves to blood vessels and muscles, thereby preventing side effects caused by allergy.
- the coating layer contains an antihistamine in an amount of 1% to 50%, 1% to 10%, 5% to 40%, 5% to 20%, 10% to 40%, or 10% by weight. It may be included in weight% to 30% by weight.
- One surface of the coating layer may have a fine needle shape.
- a substrate 10 in the patch for preventing allergy, a substrate 10, a coating layer 20 containing an antihistamine, and a release film 30 are sequentially stacked, and fine needles 21 are formed on one side of the coating layer, The release film may seal and cover the microneedle-shaped coating layer.
- the fine needle shape includes an attachment capable of being inserted into the skin and a base portion supporting it.
- the height of the microneedle may be 5 ⁇ m to 2000 ⁇ m, 50 ⁇ m to 1500 ⁇ m, or 100 ⁇ m to 1000 ⁇ m.
- the diameter of the base of the microneedle may be 5 ⁇ m to 1500 ⁇ m, 10 ⁇ m to 1000 ⁇ m, or 10 ⁇ m to 500 ⁇ m.
- the coating layer has a microneedle shape
- an effective substance such as an antihistamine to penetrate the skin when injected into the skin, thereby improving the penetration rate of the antihistamine.
- scars are not left even when the skin is inserted in the shape of a fine needle.
- the coating layer may further include a hydrogel.
- the hydrogel is prepared by crosslinking a hydrogel composition containing at least one of polyvinyl alcohol, carrageenan gum, xanthan gum, and locust bean gum.
- the coating layer when the coating layer includes a hydrogel, it may be prepared by mixing an antihistamine with the hydrogel composition to cross-link, or by impregnating the hydrogel with the antihistamine.
- the coating layer when the coating layer includes the hydrogel, when the patch for preventing allergy is attached to the skin, it is possible to properly maintain the moisture of the skin to minimize skin trouble.
- the coating layer may further include at least one antibacterial material among volcanic stone powder, oyster shell powder, and loess powder having an antibacterial and deodorizing function, and the antimicrobial material has a particle size of 30 to 100 ⁇ m.
- At least one antimicrobial additive from among marjoram extract, rhubarb extract, thyme hydrosol, pine bark extract, grape seed extract, and aronia extract may be further added to reinforce antibacterial properties.
- the release film may be formed on the surface opposite to the surface on which the substrate of the coating layer is formed.
- the release film serves to protect the coating layer by removing it when the patch for preventing allergy is attached to the skin.
- the release film is not particularly limited as long as it is a flexible polymer film.
- the patch for preventing allergy according to the present invention can be used for all allergic reactions using antihistamines to alleviate allergic reactions, but can be particularly used for preventing side effects of contrast medium or allergy due to food intake.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a patch for preventing side effects caused by allergies. A patch for allergy prevention, of the present invention, comprises a composition containing an antihistamine and has the advantages of being attached to the skin so as to be non-invasive, being usable as a precautionary measure before the appearance of symptoms of side effects caused by allergies, and being temporarily usable before arriving at a hospital. In addition, according to the present invention, even though steroids are commonly used with antihistamines for treating side effects caused by allergies, the patch of the present invention does not comprise steroids, and thus can be used even in the presence of gout.
Description
본 발명은 알레르기 반응으로 발생하는 부작용을 예방하기 위한 패치에 관한 것으로서, 기재 상에 항히스타민제를 포함하는 조성물로 형성된 코팅층을 포함하는 알레르기 예방용 패치에 관한 것이다.The present invention relates to a patch for preventing side effects caused by an allergic reaction, and relates to a patch for preventing allergy, which includes a coating layer formed on a substrate with a composition containing an antihistamine.
현대 의학에서 전산화단층영상검사(Computed tomography; CT)와 자기공명영상검사(magnetic resonance imaging; MRI)등의 영상검사는 질병의 진단을 위한 필수적 요소로 사용되는 방사선학적 검사이다. 이러한 CT검사나 MRI검사에서 조영제의 사용은 영상의 대조도를 높여 병변을 명확히 구분할수 있도록 하는데, 그 사용건수는 날로 증가하고 있다. 이러한 조영자는 인체에 주입 후 얼굴이나 가슴, 복부의 후끈거림, 환자가 느끼는 입의 약냄새, 약간의 온열감 등이 있을 수 있는데, 이는 조영제가 우리 몸속으로 혈관을 따라 퍼지면서 느끼게 되는 정상적인 반응이다.In modern medicine, imaging tests such as computed tomography (CT) and magnetic resonance imaging (MRI) are radiological tests that are used as essential elements for diagnosing diseases. The use of a contrast agent in such a CT scan or MRI scan increases the contrast of the image so that lesions can be clearly distinguished, and the number of uses is increasing day by day. After the contrast medium is injected into the human body, there may be a burning sensation in the face, chest, or abdomen, a smell of medicine in the patient's mouth, and a slight sense of warmth. These are normal reactions felt as the contrast medium spreads through blood vessels in the body.
그러나, 이러한 정상적인 반응 외에 의료진의 처치가 필요한 조영제 관련 과민반응이나 유해반응이 드물게 나타나고 있다. 조영제의 급성 유해 반응으로는 구토, 두드러기, 가려움증의 가벼운 증상에서 기관수축, 안면부종, 저혈압성 쇼크, 호흡정지 및 심정지에 이르는 중증반응까지 다양하게 나타난다.However, in addition to these normal reactions, contrast agent-related hypersensitivity reactions or adverse reactions that require treatment by medical staff are rare. Acute adverse reactions to contrast media range from mild symptoms such as vomiting, hives, and pruritus to severe reactions ranging from trachea constriction, facial edema, hypotensive shock, respiratory arrest, and cardiac arrest.
이에, 업계에서는 부작용을 줄일 수 조영제 조성물 및 조영제로 인한 부작용이 발생했을 때 증상을 효과적으로 치료하기 위한 기술개발을 요구하는 실정에 있다.Accordingly, in the industry, there is a situation in which a contrast medium composition capable of reducing side effects and a technology development for effectively treating symptoms when side effects due to the contrast medium occur are required.
이러한 업계에서의 요구에 부응함과 더불어 종래의 조영제로 인한 부작용을 최소화하기 위해 본원출원인은 다양한 연구 및 개발을 수행하고 있으며, 조영제의 종류와 관계없이 조영제로 인한 부작용이 발생하지 않도록 예방할 수 있고, 더불어 알레르기 반응으로 인한 부작용을 예방할 수 있는 기술을 제안하려고 한다.In order to meet these demands in the industry and to minimize side effects caused by conventional contrast media, the applicant of the present application is conducting various research and development, and regardless of the type of contrast media, side effects due to contrast media can be prevented from occurring, In addition, we would like to propose a technique that can prevent side effects caused by allergic reactions.
본 발명은 상술한 종래의 문제점을 해소 및 이를 감안하여 안출된 것으로서, 기재 상에 항히스타민제를 포함하는 조성물로 형성된 코팅층을 포함하는 알레르기 예방용 패치를 제공하는데 그 목적이 있다.The present invention has been made in view of and solving the above-mentioned conventional problems, and an object of the present invention is to provide a patch for preventing allergy that includes a coating layer formed of a composition containing an antihistamine on a substrate.
본 발명은 기재; 및 기재의 적어도 일면에 형성되는 항히스타민제를 포함하는 코팅층을 포함하고,The present invention is a substrate; And a coating layer containing an antihistamine formed on at least one surface of the substrate,
상기 코팅층은 항히스타민제를 포함하는 조성물을 코팅하여 형성한 것인 알레르기 예방용 패치를 제공한다.The coating layer provides a patch for preventing allergy that is formed by coating a composition containing an antihistamine.
본 발명에 따르면, 항히스타민제를 포함하는 조성물을 포함하는 패치로 피부에 부착하여 비침습적이고, 알레르기로 인한 부작용 증상 발현 이전에 예방차원에서 사용할 수 있으며, 병원에 도착하기 전까지 임시로 사용가능한 장점이 있다.According to the present invention, a patch containing a composition containing an antihistamine is non-invasive by attaching to the skin, can be used as a preventive measure prior to the onset of side effects caused by allergies, and can be used temporarily until arriving at a hospital. there is.
또한, 본 발명에 따르면, 일반적으로 알레르기로 인한 부작용을 치료하기 위해 항히스타민제와 함께 스테로이드도 사용하나, 본 발명의 패치는 스테로이드를 포함하지 않아 통풍이 있는 경우에도 사용가능한 장점이 있다.In addition, according to the present invention, steroids are generally used together with antihistamines to treat side effects caused by allergies, but the patch of the present invention does not contain steroids, so it can be used even in cases of gout.
도 1 및 도 2는 본 발명의 실시예에 따른 패치의 모식도를 나타낸 이미지이다.1 and 2 are schematic images of a patch according to an embodiment of the present invention.
본 발명은 알레르기로 인해 발생하는 부작용을 예방하기 패치에 관한 것으로, 본 발명의 알레르기 예방용 패치는 항히스타민제를 포함하는 조성물을 포함하는 패치로 피부에 부착하여 비침습적이고, 알레르기로 인한 부작용 증상 발현 이전에 예방차원에서 사용할 수 있으며, 병원에 도착하기 전까지 임시로 사용가능한 장점이 있다.The present invention relates to a patch for preventing side effects caused by allergy. The patch for preventing allergy of the present invention is a patch containing a composition containing an antihistamine, is non-invasive by being attached to the skin, and exhibits symptoms of side effects due to allergy. It can be used as a preventive measure beforehand, and has the advantage of being used temporarily until arriving at the hospital.
또한, 본 발명에 따르면, 일반적으로 알레르기로 인한 부작용을 치료하기 위해 항히스타민제와 함께 스테로이드도 사용하나, 본 발명의 패치는 스테로이드를 포함하지 않아 통풍이 있는 경우에도 사용가능한 장점이 있다.In addition, according to the present invention, steroids are generally used together with antihistamines to treat side effects caused by allergies, but the patch of the present invention does not contain steroids, so it can be used even in cases of gout.
본 발명에 대해 첨부한 도면을 참조하여 바람직한 실시예를 설명하면 다음과 같으며, 이와 같은 상세한 설명을 통해서 본 발명의 목적과 구성 및 그에 따른 특징들을 보다 잘 이해할 수 있게 될 것이다.Preferred embodiments of the present invention will be described with reference to the accompanying drawings, and through this detailed description, the purpose and configuration of the present invention and the characteristics thereof will be better understood.
본 발명은, 기재; 및 기재의 적어도 일면에 형성되는 항히스타민제를 포함하는 코팅층을 포함하는 알레르기 예방용 패치에 관한 것이다.The present invention, a substrate; and a coating layer comprising an antihistamine formed on at least one surface of a substrate.
도 1은 본 발명에 따른 알레르기 예방용 패치의 모식도를 나타낸 이미지이다. 도 1을 살펴보면, 본 발명의 알레르기 예방용 패치는 기재(10), 항히스타민제를 포함하는 코팅층(20) 및 이형필름(30)이 순차적으로 적층된 구조이다.1 is an image showing a schematic diagram of a patch for preventing allergy according to the present invention. Referring to Figure 1, the patch for preventing allergy of the present invention has a structure in which a substrate 10, a coating layer 20 containing an antihistamine, and a release film 30 are sequentially laminated.
상기 기재는 고분자 필름; 및 천연 섬유 또는 고분자 섬유로 이루어진 시트 중 어느 하나 이상을 포함할 수 있다.The substrate may include a polymer film; And it may include any one or more of sheets made of natural fibers or polymer fibers.
상기 고분자 필름은 폴리에틸렌, 폴리프로필렌, 폴리염화비닐 및 폴리우레탄 중 어느 하나 이상을 포함한다. 구체적으로, 고분자 필름은 폴리우레탄일 수 있고, 폴리우레탄을 포함하는 경우 신축성이 우수한 이점이 있다.The polymer film includes at least one of polyethylene, polypropylene, polyvinyl chloride, and polyurethane. Specifically, the polymer film may be polyurethane, and when it includes polyurethane, it has an advantage of excellent elasticity.
상기 천연 섬유는 셀룰로오스, 키틴, 키토산, 전분, 콜라겐 및 젤라틴 중 어느 하나 이상을 포함한다. 상기와 같은 천연 섬유를 사용하는 경우, 친환경적인 이점이 있다.The natural fibers include any one or more of cellulose, chitin, chitosan, starch, collagen, and gelatin. When using natural fibers as described above, there is an environmentally friendly advantage.
상기 고분자 섬유는 폴리비닐알코올, 폴리글리콜산, 폴리락트산 및 폴리카프로락톤 중 어느 하나 이상을 포함한다.The polymer fiber includes at least one of polyvinyl alcohol, polyglycolic acid, polylactic acid, and polycaprolactone.
상기 기재는 플라즈마를 이용한 표면처리하여 극성이 부여된 것일 수 있다. 이와 같이 플라즈마 표면 처리된 기재는 표면에 극성이 부여되어 코팅층과의 결합력을 더욱 향상시킬 수 있다.The substrate may be polarized by surface treatment using plasma. As described above, polarity is imparted to the surface of the substrate subjected to plasma surface treatment, so that bonding strength with the coating layer can be further improved.
상기 기재가 천연 섬유 및 고분자 섬유 중 어느 하나 이상으로 이루어진 시트인 경우, 시트 내에 캐비티가 구비되고, 상기 캐비티는 부직포의 단면을 기준으로 상하로 형성되되 상하 중 어느 하나는 닫힌 구조일 수 있다. 상기와 같은 구조의 기재를 포함하여 코팅층이 형성되었을 때 기재(시트) 하단부로 흘러내리지 않으면서도 기재 사이로 공기는 통과할 수 있다.When the substrate is a sheet made of at least one of natural fibers and polymer fibers, cavities are provided in the sheet, and the cavities are formed vertically based on the cross section of the nonwoven fabric, but either top or bottom may have a closed structure. When the coating layer is formed including the substrate having the above structure, air can pass between the substrates without flowing down to the lower end of the substrate (sheet).
상기 코팅층은 항히스타민제를 포함하는 조성물을 코팅하여 형성한 것일 수 있다. 또한, 상기 코팅층은 피부에 직접적으로 접촉하는 부위이다.The coating layer may be formed by coating a composition containing an antihistamine. In addition, the coating layer is a site in direct contact with the skin.
상기 항히스타민제는 클로르페니라민(chlorpheniramine), 트리프롤리딘(triprolidine), 피프린히드리네이트(piprinhydrinate), 히드록시진(hydroxyzine), 메퀴타진(mequitazine), 디펜히드라민(diphenhydramine), 디멘히드리네이트(dimenhydrinate), 메클리진(meclizine), 세티리진(cetirizine), 로라타딘(loratadine), 레보세티리진(levocetirizine), 에바스틴(ebastine), 케토티펜(ketotifen), 펙소페나딘(fexofenadine), 아젤라스틴(azelastine), 데스로라타딘(desloratadine), 베포타스틴(bepotastine), 올로파타딘(olopatadine), 에메다스틴(emedastine), 에피나스틴(epinastine) 및 레보카바스틴(levocabastine) 어느 하나 이상을 포함한다.The antihistamines include chlorpheniramine, triprolidine, piperinhydrinate, hydroxyzine, mequitazine, diphenhydramine, and dimenhydrin. dimenhydrinate, meclizine, cetirizine, loratadine, levocetirizine, ebastine, ketotifen, fexofenadine, azela Any one or more of azelastine, desloratadine, bepotastine, olopatadine, emedastine, epinastine, and levocabastine include
상기와 같은 항히스타민제를 코팅층에 포함하여 알레르기 예방용 패치를 피부에 부착하면 피부로 항히스타민제가 흡수되어 혈관 및 근육으로 이동하여 알레르기로 인한 부작용을 예방할 수 있다.When a patch for preventing allergy is attached to the skin by including the antihistamine in the coating layer, the antihistamine is absorbed into the skin and moves to blood vessels and muscles, thereby preventing side effects caused by allergy.
구체적으로, 상기 코팅층은 항히스타민제를 1 중량% 내지 50중량%, 1 중량% 내지 10중량%, 5 중량% 내지 40중량%, 5 중량% 내지 20중량%, 10 중량% 내지 40중량% 또는 10 중량% 내지 30중량%으로 포함할 수 있다.Specifically, the coating layer contains an antihistamine in an amount of 1% to 50%, 1% to 10%, 5% to 40%, 5% to 20%, 10% to 40%, or 10% by weight. It may be included in weight% to 30% by weight.
상기와 같은 코팅층을 포함함으로써, 알레르기로 인해 발생하는 부작용 증상을 완화시켜주고, 이에 따라 통풍이 있는 환자에 적절하지 않은 스테로이드를 포함하지 않아도 되는 이점이 있다.By including the coating layer as described above, side effects caused by allergies are alleviated, and accordingly, there is an advantage that steroids that are not suitable for patients with gout do not have to be included.
상기 코팅층의 일면은 미세침 형상일 수 있다. 도 2에 나타낸 바와 같이 알레르기 예방용 패치는 기재(10), 항히스타민제를 포함하는 코팅층(20) 및 이형필름(30)이 순차적으로 적층되되, 코팅층의 일면이 미세침(21)이 형성되고, 이형필름은 미세침 형상의 코팅층을 밀봉하여 덮을 수 있다.One surface of the coating layer may have a fine needle shape. As shown in FIG. 2, in the patch for preventing allergy, a substrate 10, a coating layer 20 containing an antihistamine, and a release film 30 are sequentially stacked, and fine needles 21 are formed on one side of the coating layer, The release film may seal and cover the microneedle-shaped coating layer.
상기 미세침 형상은 피부 자입이 가능한 첨부와 이를 지지하는 기저부를 포함한다. 미세침의 높이는 5 ㎛ 내지 2000 ㎛, 50 ㎛ 내지 1500 ㎛ 또는 100 ㎛ 내지 1000 ㎛일 수 있다. 또한, 미세침의 기저부의 직경은 5 ㎛ 내지 1500 ㎛, 10 ㎛ 내지 1000 ㎛ 또는 10 ㎛ 내지 500 ㎛일 수 있다.The fine needle shape includes an attachment capable of being inserted into the skin and a base portion supporting it. The height of the microneedle may be 5 μm to 2000 μm, 50 μm to 1500 μm, or 100 μm to 1000 μm. In addition, the diameter of the base of the microneedle may be 5 μm to 1500 μm, 10 μm to 1000 μm, or 10 μm to 500 μm.
상기와 같이 코팅층의 일면이 미세침 형상을 갖는 경우는 피부 자입시 항히스타민제와 같은 유효 물질이 피부에 침투하기 용이하여 항히스타민제 침투율을 향상시킬 수 있다. 또한, 미세침 형상으로 피부 자입시에도 흉터가 남지 않은 장점이 있다.As described above, when one surface of the coating layer has a microneedle shape, it is easy for an effective substance such as an antihistamine to penetrate the skin when injected into the skin, thereby improving the penetration rate of the antihistamine. In addition, there is an advantage that scars are not left even when the skin is inserted in the shape of a fine needle.
상기 코팅층은 하이드로겔을 더 포함할 수 있다. 상기 하이드로겔은 폴리비닐알코올, 카라기난검, 잔탄검 및 로커스트빈검 중 어느 하나 이상을 포함하는 하이드로겔 조성물을 가교하여 제조한 것이다.The coating layer may further include a hydrogel. The hydrogel is prepared by crosslinking a hydrogel composition containing at least one of polyvinyl alcohol, carrageenan gum, xanthan gum, and locust bean gum.
구체적으로, 상기 코팅층이 하이드로겔을 포함하는 경우는 항히스타민제를 상기 하이드로겔 조성물과 혼합하여 가교시키거나, 하이드로겔에 항히스타민제를 함침하여 제조한 것일 수 있다. 이와 같이 코팅층에 하이드로겔을 포함하는 경우, 알레르기 예방용 패치를 피부에 부착 시 피부의 수분을 적절하게 유지하여 피부에 발생하는 트러블을 최소화할 수 있다.Specifically, when the coating layer includes a hydrogel, it may be prepared by mixing an antihistamine with the hydrogel composition to cross-link, or by impregnating the hydrogel with the antihistamine. In this way, when the coating layer includes the hydrogel, when the patch for preventing allergy is attached to the skin, it is possible to properly maintain the moisture of the skin to minimize skin trouble.
상기 코팅층은 항균 탈취기능을 갖는 화산석분말, 굴패각분말, 황토분말 중에서 적어도 1종의 항균성재료를 더 포함할 수 있고, 상기 항균성재료는 입자크기 30~100㎛인 것을 특징으로 한다.The coating layer may further include at least one antibacterial material among volcanic stone powder, oyster shell powder, and loess powder having an antibacterial and deodorizing function, and the antimicrobial material has a particle size of 30 to 100 μm.
여기에서, 항균성을 보강하기 위해 마조람추출액, 대황추출액, 타임하이드로졸, 소나무껍질추출액, 포도씨추출액, 아로니아추출액 중에서 적어도 1종의 항균성 첨가제 5~20중량부를 더 첨가할 수 있다.Here, 5 to 20 parts by weight of at least one antimicrobial additive from among marjoram extract, rhubarb extract, thyme hydrosol, pine bark extract, grape seed extract, and aronia extract may be further added to reinforce antibacterial properties.
상기 이형필름은 코팅층의 기재가 형성된 면의 반대면에 형성될 수 있다. 상기 이형필름은 알레르기 예방용 패치를 피부에 부착할 때 제거하는 것으로, 코팅층을 보호하는 역할을 한다.The release film may be formed on the surface opposite to the surface on which the substrate of the coating layer is formed. The release film serves to protect the coating layer by removing it when the patch for preventing allergy is attached to the skin.
상기 이형필름은 유연한 고분자 필름 종류라면 특별히 제한되지 않는다.The release film is not particularly limited as long as it is a flexible polymer film.
본 발명에 따른 알레르기 예방용 패치는 알레르기 반응을 완화시키기 위해 항히스타민제를 사용하는 알레르기 반응에 모두 사용가능하나, 특히 조영제 부작용 예방용 또는 음식물 섭취로 인한 알레르기 예방용으로 사용될 수 있다.The patch for preventing allergy according to the present invention can be used for all allergic reactions using antihistamines to alleviate allergic reactions, but can be particularly used for preventing side effects of contrast medium or allergy due to food intake.
Claims (8)
- 기재; 및write; and상기 기재의 적어도 일면에 형성되는 항히스타민제를 포함하는 코팅층을 포함하고,A coating layer containing an antihistamine formed on at least one surface of the substrate,상기 코팅층은 항히스타민제를 포함하는 조성물을 코팅하여 형성한 것인 알레르기 예방용 패치.The coating layer is a patch for preventing allergy that is formed by coating a composition containing an antihistamine.
- 제1항에 있어서,According to claim 1,상기 코팅층은 하이드로겔 성분을 더 포함하는 알레르기 예방용 패치.The coating layer is a patch for preventing allergy further comprising a hydrogel component.
- 제1항에 있어서,According to claim 1,상기 코팅층의 기재가 형성된 면의 반대면은 이형필름을 포함하는 알레르기 예방용 패치.The opposite side of the surface on which the substrate of the coating layer is formed is a patch for preventing allergy comprising a release film.
- 제1항에 있어서,According to claim 1,상기 항히스타민제는 클로르페니라민(chlorpheniramine), 트리프롤리딘(triprolidine), 피프린히드리네이트(piprinhydrinate), 히드록시진(hydroxyzine), 메퀴타진(mequitazine), 디펜히드라민(diphenhydramine), 디멘히드리네이트(dimenhydrinate), 메클리진(meclizine), 세티리진(cetirizine), 로라타딘(loratadine), 레보세티리진(levocetirizine), 에바스틴(ebastine), 케토티펜(ketotifen), 펙소페나딘(fexofenadine), 아젤라스틴(azelastine), 데스로라타딘(desloratadine), 베포타스틴(bepotastine), 올로파타딘(olopatadine), 에메다스틴(emedastine), 에피나스틴(epinastine) 및 레보카바스틴(levocabastine) 어느 하나 이상을 포함하는 알레르기 예방용 패치.The antihistamines include chlorpheniramine, triprolidine, piperinhydrinate, hydroxyzine, mequitazine, diphenhydramine, and dimenhydrin. dimenhydrinate, meclizine, cetirizine, loratadine, levocetirizine, ebastine, ketotifen, fexofenadine, azela Any one or more of azelastine, desloratadine, bepotastine, olopatadine, emedastine, epinastine, and levocabastine Allergy prevention patch containing.
- 제1항에 있어서,According to claim 1,상기 기재는 플라즈마를 이용한 표면처리하여 극성이 부여된 것을 특징으로 하는 알레르기 예방용 패치.The substrate is a patch for preventing allergy, characterized in that polarity is imparted by surface treatment using plasma.
- 제1항에 있어서,According to claim 1,상기 코팅층은 화산석분말, 굴패각분말, 황토분말 중에서 적어도 1종의 항균성재료를 더 포함하는 알레르기 예방용 패치.The coating layer is a patch for preventing allergy further comprising at least one antibacterial material from among volcanic stone powder, oyster shell powder, and ocher powder.
- 제1항에 있어서,According to claim 1,상기 코팅층의 일면은 미세침 형상인 것을 특징으로 하는 알레르기 예방용 패치.One side of the coating layer is a patch for preventing allergy, characterized in that the fine needle shape.
- 제1항에 있어서,According to claim 1,상기 알레르기 예방용 패치는 조영제 부작용 예방용 또는 음식물 섭취로 인한 알레르기 예방용인 것을 특징으로 하는 알레르기 예방용 패치.The patch for preventing allergy, characterized in that for preventing side effects of the contrast medium or preventing allergy due to food intake.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2021/018172 WO2023101061A1 (en) | 2021-12-03 | 2021-12-03 | Patch for allergy prevention |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2021/018172 WO2023101061A1 (en) | 2021-12-03 | 2021-12-03 | Patch for allergy prevention |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023101061A1 true WO2023101061A1 (en) | 2023-06-08 |
Family
ID=86612449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2021/018172 WO2023101061A1 (en) | 2021-12-03 | 2021-12-03 | Patch for allergy prevention |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2023101061A1 (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110114195A (en) * | 2010-04-13 | 2011-10-19 | (주)글로벌첼린지 | Hydrogel patch mixed inorganic materials for pets, and their process |
| KR20120122197A (en) * | 2011-04-28 | 2012-11-07 | 한스바이오메드 주식회사 | Silicon gel sheet for preventing and alleviating atopic dermatitis |
| KR20170124322A (en) * | 2016-05-02 | 2017-11-10 | 주식회사 엘지생활건강 | Soluble microneedle patch for delivery of antiallergic drugs |
| US20190183405A1 (en) * | 2016-08-12 | 2019-06-20 | Industry-Academic Cooperation Foundation, Yonsei University | Micro-needle patch, method for manufacturing the micro-needle patch, and method for diagnosing allergy disease using the micro-needle patch |
| KR20190102242A (en) * | 2016-12-30 | 2019-09-03 | 유로메드 인코포레이티드 | Adhesive Patches with Improved Release Liner System |
| KR20220068372A (en) * | 2020-11-19 | 2022-05-26 | 가톨릭관동대학교산학협력단 | Patch for preventing allergy |
-
2021
- 2021-12-03 WO PCT/KR2021/018172 patent/WO2023101061A1/en unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110114195A (en) * | 2010-04-13 | 2011-10-19 | (주)글로벌첼린지 | Hydrogel patch mixed inorganic materials for pets, and their process |
| KR20120122197A (en) * | 2011-04-28 | 2012-11-07 | 한스바이오메드 주식회사 | Silicon gel sheet for preventing and alleviating atopic dermatitis |
| KR20170124322A (en) * | 2016-05-02 | 2017-11-10 | 주식회사 엘지생활건강 | Soluble microneedle patch for delivery of antiallergic drugs |
| US20190183405A1 (en) * | 2016-08-12 | 2019-06-20 | Industry-Academic Cooperation Foundation, Yonsei University | Micro-needle patch, method for manufacturing the micro-needle patch, and method for diagnosing allergy disease using the micro-needle patch |
| KR20190102242A (en) * | 2016-12-30 | 2019-09-03 | 유로메드 인코포레이티드 | Adhesive Patches with Improved Release Liner System |
| KR20220068372A (en) * | 2020-11-19 | 2022-05-26 | 가톨릭관동대학교산학협력단 | Patch for preventing allergy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3896802A (en) | Flexible flocked dressing | |
| US5895656A (en) | Gas or gel-filled silicone cushion for treatment of keloid and hypertrophic scars | |
| US20110028831A1 (en) | Permanently visible implantable fiduciary tissue marker | |
| DE69932311T2 (en) | Wrinkle resistant bandage | |
| JPH02500819A (en) | Vapor permeable dressing | |
| US20210244856A1 (en) | Composite implant material | |
| CN107437438A (en) | Radiation protection system | |
| KR102481717B1 (en) | Patch for preventing allergy | |
| JP2011516462A (en) | Biocompatible materials for magnetic particle imaging | |
| WO2023101061A1 (en) | Patch for allergy prevention | |
| AU2014348720B2 (en) | Hemostatic products | |
| Singh et al. | A tunable soft silicone bioadhesive for secure anchoring of diverse medical devices to wet biological tissue | |
| WO2020226254A1 (en) | Improved wound dressing member | |
| CN108543165A (en) | A kind of muscular function auxiliary device based on carrier | |
| CN207886353U (en) | A kind of analgesia promoting healing functional dressing | |
| CN111789711A (en) | Dressing device for treating gastric ulcer under endoscope | |
| CN206852710U (en) | A kind of foam dressing for being easy to implantation of heart pacemaker postoperative care | |
| KR100644377B1 (en) | Backing film having elasticity | |
| Miller et al. | Problems related to the maintenance of chronic percutaneous electronic leads | |
| CN107468420A (en) | Puncture hole fixes application | |
| CN207024155U (en) | A kind of sternal fixation device | |
| Singh et al. | MA, USA. | |
| CN110025815A (en) | It is a kind of for anal intestine to be postoperative and the postoperative silver ion dressing and preparation method thereof of gynaecology | |
| CN215875222U (en) | Medical application medicine box with disinfection and anesthesia effects | |
| CN118401205A (en) | Non-traumatic absorbent wound dressing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21966487 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |